Global Neuroendocrine Tumor Treatment Market to Surpass US$ 3,244.7 Million by 2027 - Coherent Market Insights

Date : 26/03/2020 @ 13:29
Source : PR Newswire (US)

Global Neuroendocrine Tumor Treatment Market to Surpass US$ 3,244.7 Million by 2027 - Coherent Market Insights

SEATTLE, March 26, 2020 /PRNewswire/ -- According to Coherent Market Insights, the global neuroendocrine tumor treatment market is estimated to be valued at US$ 1,448.1 Mn in 2019 and is expected to exhibit a CAGR of 10.6% during the forecast period (2019-2027).

Coherent_Market_Insights_Logo

Key Trends and Analysis of the Global Neuroendocrine Tumor Treatment Market:

The increasing approvals and launches of such novel therapies in the market is expected to drive growth of the global neuroendocrine tumor treatment market over the forecast period. For instance, in February 2016, Novartis received the U.S. Food and Drug Administration approval for its Afinitor (everolimus) tablets, which is indicated in adult patients for the treatment of progressive, non-functional gastrointestinal (GI), and lung neuroendocrine tumors (NET).

The rising prevalence of different types of neuroendocrine tumors such as gastrointestinal NET, pancreatic NET, lung NET, and other NET is expected to fuel demand for neuroendocrine tumor treatment drugs and therapies. For instance, according to the American Cancer Society estimation, in 2020, around 4,032 people will be diagnosed with pancreatic NET in the U.S.

Request for Sample PDF copy @ https://www.coherentmarketinsights.com/insight/request-sample/129 

Key players in market are increasingly focusing on research and development activities, in order to develop advanced therapies for the treatment of neuroendocrine tumor. For instance, in October 2019, Ochsner Health System and Merck Sharp & Dohme Corp. collaboratively initiated phase 2 clinical trial to study the efficacy, safety, and tolerability of Pembrolizumab (MK-3475) in combination with chemotherapy agents Cisplatin or carboplatin and etoposide) in the patients with high grade gastroenteropancreatic neuroendocrine tumors (GEPNETs) and neuroendocrine carcinomas of the lung. The study is estimated to complete in December 2021. Such increasing clinical trials is anticipated to witness robust growth for neuroendocrine tumor treatment market in near future.

Among regions, Asia Pacific is expected to witness significant growth in the neuroendocrine tumor treatment market over the forecast period, owing to presence of major players in the region such as Hutchison Medipharma Limited (Chi- Med). In January 2020, Hutchison Medipharma Limited announced that its SANET-p Study, a phase III study for Surufatinib achieved its primary end-point in the treatment of low-grade or intermediate-grade advanced pancreatic neuroendocrine tumor patients. This positive result for Surufatinib (SANET-p) study is expected to introduce prominent treatment options for the patients with pancreatic neuroendocrine tumor.

Key Market Takeaways:

  • The global neuroendocrine tumor treatment market is expected to exhibit a CAGR of 10.6% over the forecast period (2019-2027), owing to increasing pipeline products for the treatment of neuroendocrine tumors. For instance, in December 2016, Tarveda Therapeutics initiated phase 1/2a clinical trial study to evaluate the safety and efficacy of PEN-221 in patients with somatostatin receptor 2 (SSTR2) expressing advanced cancers including neuroendocrine and small cell lung cancers.
  • Among indication, gastrointestinal NET segment, is expected to witness significant growth in the neuroendocrine tumor treatment market over the forecast period, owing to increasing product approvals and launches for the treatment of gastrointestinal NET. For instance, in January 2018, the U.S. Food and Drug Administration (FDA) approved lutetium Lu 177 dotatate (Lutathera) for the treatment of advanced NETs affecting pancreas or gastrointestinal tract in the adult patients.

Major players operating in the global neuroendocrine tumor treatment market include—

Pfizer Inc, Novartis AG, Ispen, Advanced Accelerator Applications, Tarveda Therapeutics, Progenics Pharmaceuticals, Inc., Hutchison Medipharma Limited, Dauntless Pharmaceuticals Inc., and Exelixis, Inc.

Buy this Report Now @ https://www.coherentmarketinsights.com/insight/buy-now/129 

Market Segmentations:

  • Global Neuroendocrine Tumor Treatment Market, By Treatment Type :
    • Somatostatin Analogues (SSAs)
      • Octreotide
      • Lanreotide
      • Others
    • Targeted Therapy
    • Chemotherapy
    • Others
  • Global Neuroendocrine Tumor Treatment Market, By Indication:
    • Gastrointestinal NET
    • Lung NET
    • Pancreatic NET
    • Other NET
  • Global Neuroendocrine Tumor Treatment Market, By End User:
    • Hospitals
    • Oncology Centers
    • Others
  • Global Neuroendocrine Tumor Treatment Market, By Region:
    • North America
      • By Country:
        • U.S.
        • Canada
    • Europe
      • By Country:
        • U.K.
        • Germany
        • Italy
        • Spain
        • France
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Country:
        • Australia
        • India
        • China
        • Japan
        • ASEAN
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Middle East
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa

Did not find what you were looking for? Here are some similar topics:

RENAL BIOMARKERS MARKET

Chronic kidney disease (CKD) involves gradual loss of functioning of kidneys. The normal function of kidneys are to filter out and excrete wastes, and excess fluids from the blood are excreted through urine. However, when an individual is suffering from chronic kidney disease, kidneys cannot perform their natural function and wastes, fluids, and electrolytes build up in the body in excess amounts.

Read more @ https://www.coherentmarketinsights.com/market-insight/renal-biomarkers-market-3551 

HIGH CONTENT SCREENING MARKET

High content screening involves identification of substances such as peptides, small molecules, and others and how they affects phenotype of a cell. High content screening is used in biological research and drug discovery. It involves incubations of cells with a substance or a drug candidate, and later the structure and molecular components of the cells are analyzed.

Read more @ https://www.coherentmarketinsights.com/market-insight/high-content-screening-market-3487 

WESTERN BLOTTING MARKET

Western blotting is a technique used for detection of protein. It is also called as immunoblotting technique wherein specific antibodies are used to detect antigens. It works on the principle of molecular weight of the proteins and specificity. Gel electrophoresis is used for the denaturation of proteins and to obtain the primary antibody. Blotting and testing is performed later where the primary antibody binds to its specific antigen.

Read more @ https://www.coherentmarketinsights.com/market-insight/western-blotting-market-2711 

Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave. 
#3200 
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

 

Cision View original content:http://www.prnewswire.com/news-releases/global-neuroendocrine-tumor-treatment-market-to-surpass-us-3-244-7-million-by-2027--coherent-market-insights-301030256.html

SOURCE Coherent Market Insights

Copyright 2020 PR Newswire

$
ADVFN Advertorial
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20200329 09:00:19